(Q40895430)

24 September 2017

1 reference

title

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? (English)

1 reference

24 September 2017

0 references

Teixeira MM

1

1 reference

24 September 2017

Gristwood RW

series ordinal

2

1 reference

24 September 2017

Cooper N

series ordinal

3

1 reference

24 September 2017

Hellewell PG

series ordinal

4

1 reference

24 September 2017

1 May 1997

1 reference

Trends in Pharmacological Sciences

24 September 2017

1 reference

24 September 2017

18

1 reference

24 September 2017

164-171

1 reference

24 September 2017

5

1 reference

Inhaled glucocorticoids for asthma

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Mucosal inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Long lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Delayed protection of the heart against ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra NeuronsIn Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Locally produced tumor necrosis factor-alpha mediates interleukin-2-induced lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of rolipram on responses to acute and chronic antigen exposure in monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by the type 4 phosphodiesterase (PDE-4) inhibitor, denbufylline

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

1 reference

7 January 2021

Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Agents That Elevate cAMP Inhibit Human Neutrophil Apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effect of TNF alpha production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

TNF modulates endothelial properties by decreasing cAMP

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The value of maintenance theophylline in steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Role of phosphodiesterases in the regulation of endothelial permeability in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Inhibition of lipopolysaccharide-induced bowel erythrocyte extravasation in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2897%2901049-3

7 January 2021

10.1016/S0165-6147(97)01049-3

Identifiers

DOI

1 reference

24 September 2017

1 reference